Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹2,676Cr
Rev Gr TTM
Revenue Growth TTM
2.07%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

FCL
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 13.4 | -2.6 | 8.2 | 26.8 | 11.1 | 7.3 | 0.3 | -9.1 | -21.7 | -3.4 | -5.5 | 45.9 |
| 105 | 101 | 107 | 98 | 115 | 107 | 109 | 92 | 99 | 112 | 107 | 149 |
Operating Profit Operating ProfitCr |
| 23.8 | 23.8 | 26.3 | 29.1 | 25.0 | 24.8 | 25.0 | 27.2 | 17.8 | 18.4 | 22.5 | 19.0 |
Other Income Other IncomeCr | 2 | 4 | 4 | 5 | 4 | 5 | 7 | 5 | 8 | 9 | 8 | 7 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 3 | 3 | 3 |
| 33 | 34 | 40 | 44 | 40 | 38 | 41 | 36 | 26 | 31 | 35 | 38 |
| 7 | 8 | 9 | 11 | 10 | 8 | 9 | 9 | 6 | 6 | 9 | 8 |
|
Growth YoY PAT Growth YoY% | 52.9 | 28.7 | 51.7 | 46.5 | 17.2 | 11.7 | 1.8 | -15.5 | -34.0 | -14.2 | -18.7 | 8.2 |
| 18.9 | 19.8 | 21.7 | 23.8 | 19.9 | 20.6 | 22.0 | 22.1 | 16.8 | 18.3 | 18.9 | 16.4 |
| 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| 17.7 | 7.8 | 15.6 | 11.1 | 29.2 | 7.7 | 11.3 | 68.5 | 40.4 | 10.1 | -6.3 | 8.4 |
| 85 | 82 | 98 | 111 | 148 | 162 | 178 | 297 | 404 | 421 | 406 | 466 |
Operating Profit Operating ProfitCr |
| 16.2 | 25.7 | 23.2 | 21.2 | 18.9 | 17.7 | 18.6 | 19.3 | 21.8 | 26.1 | 23.9 | 19.4 |
Other Income Other IncomeCr | 5 | 2 | 10 | 5 | 1 | -11 | 17 | 6 | 7 | 17 | 24 | 31 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 6 | 9 | 11 |
| 20 | 29 | 38 | 34 | 34 | 22 | 56 | 73 | 115 | 158 | 141 | 131 |
| 6 | 9 | 9 | 10 | 9 | 8 | 11 | 16 | 25 | 37 | 32 | 30 |
|
| 86.7 | 38.7 | 43.6 | -17.6 | 1.5 | -41.2 | 211.4 | 27.7 | 57.4 | 35.1 | -9.8 | -7.2 |
| 14.3 | 18.4 | 22.9 | 17.0 | 13.3 | 7.3 | 20.4 | 15.4 | 17.3 | 21.3 | 20.5 | 17.5 |
| 1.1 | 0.1 | 0.3 | 0.2 | 0.2 | 0.1 | 0.4 | 0.5 | 0.8 | 1.1 | 0.9 | 0.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 23 | 23 |
| 54 | 69 | 90 | 113 | 137 | 147 | 187 | 240 | 327 | 425 | 708 | 756 |
Current Liabilities Current LiabilitiesCr | 19 | 18 | 20 | 19 | 29 | 31 | 50 | 68 | 64 | 89 | 67 | 78 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 9 | 12 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 45 | 50 | 59 | 72 | 108 | 115 | 166 | 232 | 224 | 286 | 261 | 313 |
Non Current Assets Non Current AssetsCr | 56 | 65 | 81 | 89 | 86 | 92 | 101 | 108 | 199 | 262 | 554 | 564 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 14 | 14 | 19 | 6 | 12 | 28 | 9 | 13 | 107 | 97 | 69 |
Investing Cash Flow Investing Cash FlowCr | -12 | -10 | -11 | -9 | 4 | -19 | -7 | -1 | -102 | -46 | -273 |
Financing Cash Flow Financing Cash FlowCr | -3 | -1 | -6 | -4 | -3 | -4 | -4 | -6 | -6 | -24 | 176 |
|
Free Cash Flow Free Cash FlowCr | 8 | 12 | 14 | 4 | 4 | 22 | -15 | -9 | 88 | 49 | 1 |
| 93.4 | 67.3 | 65.8 | 26.5 | 49.4 | 198.2 | 20.6 | 23.5 | 119.8 | 80.2 | 63.5 |
CFO To EBITDA CFO To EBITDA% | 82.7 | 48.3 | 64.9 | 21.2 | 34.9 | 81.5 | 22.7 | 18.8 | 95.3 | 65.4 | 54.5 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 250 | 363 | 381 | 651 | 456 | 165 | 729 | 1,995 | 2,579 | 4,081 | 2,632 |
Price To Earnings Price To Earnings | 19.6 | 20.7 | 14.7 | 28.6 | 20.3 | 12.7 | 17.1 | 36.2 | 29.2 | 34.0 | 24.3 |
Price To Sales Price To Sales | 2.5 | 3.3 | 3.0 | 4.6 | 2.5 | 0.8 | 3.3 | 5.4 | 5.0 | 7.2 | 4.9 |
Price To Book Price To Book | 3.3 | 4.0 | 3.4 | 4.8 | 2.9 | 1.0 | 3.5 | 7.6 | 7.4 | 9.1 | 3.6 |
| 14.6 | 12.7 | 12.5 | 21.6 | 12.9 | 4.3 | 17.2 | 27.5 | 22.4 | 27.3 | 20.4 |
Profitability Ratios Profitability Ratios |
| 33.1 | 42.1 | 41.3 | 39.5 | 35.5 | 37.3 | 35.7 | 36.1 | 34.4 | 38.7 | 38.6 |
| 16.2 | 25.7 | 23.2 | 21.2 | 18.9 | 17.7 | 18.6 | 19.3 | 21.8 | 26.1 | 23.9 |
| 14.3 | 18.4 | 22.9 | 17.0 | 13.3 | 7.3 | 20.4 | 15.4 | 17.3 | 21.3 | 20.5 |
| 26.5 | 31.6 | 34.0 | 24.6 | 21.4 | 13.1 | 26.6 | 28.1 | 32.5 | 35.1 | 19.5 |
| 19.1 | 22.2 | 25.8 | 17.7 | 15.3 | 8.4 | 21.3 | 21.7 | 25.7 | 27.1 | 14.9 |
| 14.5 | 17.7 | 20.8 | 14.9 | 12.5 | 6.9 | 16.7 | 16.8 | 21.2 | 22.1 | 13.4 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Fineotex Chemical Limited (**FCL**) is a leading Indian multinational specialty performance chemical manufacturer. The company has evolved from a textile-centric player into a diversified global platform providing sustainable, technology-driven solutions across the entire value chain of the **Textile**, **Oil & Gas**, **Water Treatment**, and **Cleaning & Hygiene** industries.
Operating as a **zero-debt** entity with a robust cash reserve of over **₹350 crore**, FCL focuses on high-entry-barrier specialty formulations rather than commodity products. The company manages a vast portfolio of over **1,600 SKUs** and **470+ product categories**, serving approximately **70 countries**.
---
### **Strategic Market Diversification & Product Verticals**
FCL’s business model is built on "Green Chemistry," focusing on reducing utility costs (water, steam, energy) and environmental impact (BOD/COD levels) for its clients.
| Segment | Key Solutions & Applications | Strategic Positioning |
|:---|:---|:---|
| **Textile Specialty** | Pre-treatment, Dyeing, Printing, and Finishing (Softeners, Silicones, Enzymes). | Focus on **Finishing** (**60%** of textile revenue); high customer stickiness due to technical switching risks. |
| **Oil & Gas** | Demulsifiers, Corrosion inhibitors, Biocides, and advanced fluid additives. | Targeting the **$11.5 billion** North American market via the **CrudeChem** acquisition. |
| **Cleaning & Hygiene** | Floor cleaners, hand-washes, and specialized housekeeping care. | Fungible capacities allow rapid shifts to serve brands like **Patanjali** and **Ghadi**. |
| **Water Treatment** | **Diquest** brand polymers, scale inhibitors, and coagulants. | Addressing **Zero Liquid Discharge (ZLD)** mandates and industrial flow efficiency. |
#### **Innovation Spotlight: AquaStrike Premium**
FCL recently launched **AquaStrike Premium**, a next-generation biotechnology-based mosquito control solution formulated with **Azadirachtin**.
* **Regulatory Status:** Approved by the **Central Insecticide Board (India)** and declared a **Non-Pesticide** in Malaysia.
* **Safety:** Certified non-toxic by **NSF** even in drinkable water; it replaces traditional gaseous chemical spraying with a non-toxic liquid film.
---
### **Global Manufacturing Footprint & Capacity Expansion**
FCL is aggressively scaling its infrastructure to meet a volume growth target that saw a **39% Y-o-Y** increase in **Q3 FY26**. Total global capacity is projected to reach **200,000 MTPA** by March 2026.
| Facility Location | Capacity (MTPA) | Status / Strategic Role |
|:---|:---|:---|
| **Ambernath, India** | **119,000** | Primary hub; includes a new **15,000 MTPA** specialty unit and a **100kWp Solar Plant**. |
| **Midland, Texas (USA)** | **68,000** | Commissioned **March 2026**; serves the Permian Basin energy region. |
| **Mahape, India** | **36,500** | Modern infrastructure with **GMP** and **FDA** pharma approvals. |
| **Selangor, Malaysia** | **6,500** | Operated by **Biotex**; the global hub for R&D and high-end raw materials. |
---
### **The North American Energy Pivot: CrudeChem Acquisition**
A cornerstone of FCL’s growth strategy is the **December 2025** acquisition of a **53.33%** controlling stake in **CrudeChem Technologies (CCT)**.
* **Objective:** Build a **$200 million** oilfield chemical business.
* **Infrastructure:** A new **15-acre** facility in Midland, Texas, integrates blending, R&D, and logistics.
* **Synergy:** Enables cross-selling of FCL’s sustainable chemistries into the L48 energy region, focusing on ESG-compliant oilfield solutions.
---
### **Research, Development & Sustainability Ecosystem**
FCL operates as a "solution provider," leveraging a **NABL-accredited** laboratory and global partnerships to prevent product obsolescence.
* **Strategic Alliances:** Collaborations with **EuroDye-CTC** (Belgium) for dyeing, **HealthGuard** (Australia) for anti-microbials, and the **Sasmira Institute** (India) for a state-of-the-art textile R&D center.
* **Green Chemistry:** Approximately **44%** of revenue is derived from eco-friendly chemistries.
* **Certifications:** **Bluesign®** partner, **ZDHC** contributor, **GOTS**, **ISO 14001**, and **EcoVadis** Commitment Badge.
* **Customer Centricity:** Technical teams of **44+ experts** provide on-site troubleshooting, typically resolving complaints within **2 days**.
---
### **Financial Performance & Capital Structure**
FCL maintains a disciplined, "net debt neutral" profile, funding expansion primarily through internal accruals and strategic equity raises.
#### **Consolidated Financial Metrics**
| Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|:---|:---|:---|:---|
| **Total Income (₹ Cr)** | **557.64** | **585.51** | **517.00** |
| **EBITDA Margin (%)** | **23.85%** | **26.08%** | **21.78%** |
| **PAT (₹ Cr)** | **109.21** | **121.03** | **89.55** |
| **ROCE (%)** | **~34%** | **34.35%** | **-** |
#### **Capital Restructuring (Late 2025)**
To improve market liquidity and reward shareholders, FCL executed:
* **Stock Split:** Sub-division from face value **₹2** to **₹1**.
* **Bonus Issue:** A **4:1** bonus allotment in October 2025.
* **Fundraising:** Raised **₹342.55 crore** via preferential allotments to fund inorganic growth.
* **Credit Rating:** Upgraded to **ICRA A+ (Positive)** and **ICRA A1+**.
---
### **Risk Management & Mitigation Framework**
FCL employs an **Enterprise Risk Management Programme** to navigate the complexities of the specialty chemical sector.
* **Raw Material Volatility:** Mitigated by a flexible pricing model that maintains **20-25% Operating Profit Margins** despite fluctuations in crude-linked intermediates.
* **Geopolitical Risk:** Export share recently dipped to **19%** due to instability in **Bangladesh**; however, the company is diversifying via the **India-UK** and **India-EU FTAs**, which are expected to provide zero-duty access.
* **Financial Risks:**
* **Forex:** Managed through **natural hedging**.
* **Credit:** No significant concentration risk due to a highly distributed customer base.
* **Liquidity:** Strong cash position of **₹352 crore** ensures all expansion is well-capitalized.
* **Regulatory Compliance:** Early adoption of **ZDHC** and **REACH** standards mitigates the risk of tightening environmental laws.